Business
Appointment of part-time Head of Finance
Appointment of part-time Head of Finance.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 9357W Physiomics PLC 03 May 2016 \n\nPhysiomics plc \n(\"Physiomics\") or (\"the Company\")\n \nAppointment of Anthony Clayden as part-time Head of Finance\n \n \nThe Company announces that Anthony Clayden, of Strategic Finance Director Limited, has been appointed Head of Finance to lead the financial management and provide company secretarial services with effect from 1 May 2016. This is not a board position, and Anthony is not being appointed a director or officer of Physiomics. At the same time the existing Financial Controller and Company Secretary, Liz King will step down from these duties but will remain available to support a transition.\n \nAnthony has broad experience advising on strategy and managing the finance function in a variety of companies of differing size and complexity. Anthony's career has encompassed advising a number of businesses in the life sciences and healthcare sector. This includes over 6 years as Chief Financial Officer and Company Secretary of AIM quoted Futura Medical plc including preparation for and IPO on AIM and a series of placings during his tenure.\n \nPaul Harper commented \"We are pleased to announce the addition of Anthony to the senior management team with his AIM, sector and financial experience. On behalf of the Board I wish to thank Liz for her work at Physiomics and wish her well for the future.\"\n \n \nEnquiries:\n \nPhysiomics plc \nDr Jim Millen, CEO\n+44 (0)1865 784 980\n \n \nWH Ireland Limited (broker/nomad)\nKaty Mitchell\n+44 (0) 161 832 2174\n \n \n \nAbout Physiomics plc\n \nPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, f...